The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy for Mismatch Repair Proficient ( pMMR )/Microsatellite Stable ( MSS ) Colorectal Cancer Liver Metastases ( CRLM )
Cancer Medicine · 2026-03 · 15 (3)
DOI: 10.1002/cam4.71663 ↗At a glance
Journal article in Cancer Medicine, published online on 2026-03-08. Written by Yawei Li and 5 co-authors. Institution: Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical…. Major MEDLINE topics: Liver Neoplasms, Colorectal Neoplasms, DNA Mismatch Repair, Antineoplastic Combined Chemotherapy Protocols. 26 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Fundation of China, The CAMS Innovation Fund for Medical Sciences (CIFMS), The CAMS Innovation Fund for Medical Science (CIFMS) to Xiao Li.
Topics: Onkologische Pflege
Abstract (original language)
Purpose
To assess the effectiveness and safety of hepatic arterial infusion chemotherapy (HAIC) in patients with mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer liver metastases (CRLM) who are resistant to standard treatments.
Methods
This study retrospectively evaluated 137 consecutive patients with pMMR/MSS CRLM who underwent HAIC from July 2019 to September 2023. Progression‐free survival (PFS) was the primary outcome, with secondary outcomes being overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. The Cox proportional hazards model was used to identify prognostic factors for survival.
Results
In total, 78 patients participated, with a median age of 58 years (IQR, 50.75–64.00), and 50 were male. Among these, 28 were treated with a combination of HAIC and targeted therapy, whereas 50 were given HAIC monotherapy. For all patients, the median PFS and OS were 5.10 months (95% CI: 2.85, 7.35) and 16.80 months (95% CI: 13.07, 20.53), respectively. The ORR and DCR for intrahepatic lesions were 1.37% and 58.9%, respectively. All lesions had an ORR of 2.74% and a DCR of 30.14%. The 1‐year OS rate was 67.63 (95% CI, 57.22, 79.91). Patients undergoing HAIC, whether with or without targeted therapy, showed no significant differences in ORR and DCR. Multivariable analysis showed that the combination of HAIC and targeted therapy was not an independent risk factor for PFS and OS. No adverse events of grade 4 or higher were observed.
Conclusion
HAIC shows effectiveness and tolerance in pMMR/MSS CRLM patients who are refractory to systemic therapy. However, the additive value of targeted therapy for HAIC in these patients needs to be further investigated.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID profiles: Yawei Li
Funding
- National Natural Science Fundation of China
- The CAMS Innovation Fund for Medical Sciences (CIFMS)
- The CAMS Innovation Fund for Medical Science (CIFMS) to Xiao Li
Cite
APA
Li, Y., Xi, J., Huang, X., Luo, Y., Zhang, X., & Li, X. (2026). The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy for Mismatch Repair Proficient ( pMMR )/Microsatellite Stable ( MSS ) Colorectal Cancer Liver Metastases ( CRLM ). Cancer Medicine, 15(3). https://doi.org/10.1002/cam4.71663
Vancouver
Li Y, Xi J, Huang X, Luo Y, Zhang X, Li X. The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy for Mismatch Repair Proficient ( pMMR )/Microsatellite Stable ( MSS ) Colorectal Cancer Liver Metastases ( CRLM ). Cancer Medicine. 2026;15(3). doi:10.1002/cam4.71663
BibTeX
@article{Li2026,
author = {Li, Yawei and Xi, Junqing and Huang, Xiaoyu and Luo, Yingen and Zhang, Xiaowu and Li, Xiao},
title = {The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy for Mismatch Repair Proficient ( pMMR )/Microsatellite Stable ( MSS ) Colorectal Cancer Liver Metastases ( CRLM )},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {3},
doi = {10.1002/cam4.71663}
}
EUVIMED